Research Analysts Offer Predictions for PHIO FY2025 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Analysts at HC Wainwright increased their FY2025 earnings per share estimates for Phio Pharmaceuticals in a report issued on Thursday, November 20th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($1.75) per share for the year, up from their previous estimate of ($1.80). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.95) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01.

PHIO has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen downgraded Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.00.

Phio Pharmaceuticals Trading Down 5.9%

Shares of NASDAQ PHIO opened at $1.12 on Monday. The stock has a market cap of $6.41 million, a price-to-earnings ratio of -0.34 and a beta of 0.96. Phio Pharmaceuticals has a 52 week low of $0.97 and a 52 week high of $9.79. The company’s 50-day moving average price is $1.98 and its 200 day moving average price is $2.14.

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the period. Geode Capital Management LLC owned 1.20% of Phio Pharmaceuticals worth $136,000 as of its most recent SEC filing. 57.31% of the stock is currently owned by hedge funds and other institutional investors.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.